Rebif (human IFN-β-1a) / EMD Serono  >>  Phase 3
Welcome,         Profile    Billing    Logout  

38 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rebif (human IFN-β-1a) / EMD Serono
ACTRN12608000435381: Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study One

Active, not recruiting
3
581
 
Genzyme Corporation, Genzyme Corporation, Bayer Schering Pharma AG
Multiple Sclerosis, Relapsing-Remitting
 
 
ACTRN12608000426381: Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study Two

Active, not recruiting
3
700
 
Genzyme Corporation, Genzyme Corporation, Bayer Schering Pharma AG
Multiple Sclerosis, Relapsing-Remitting
 
 
NCT00292266: A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

Completed
3
677
US
Rebif®, Avonex®
EMD Serono, Merck Serono International SA
Multiple Sclerosis, Relapsing-Remitting
06/02
06/02
NCT00292253: Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects

Completed
3
1883
US
Rebif® via Rebiject™Mini, Rebif® via manual injections
EMD Serono, Merck Serono International SA
Multiple Sclerosis, Relapsing-remitting
12/02
12/02
2004-004130-14: A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with relapsing multiple sclerosis previously treated with Interferon beta-1a (22 or 44 mcg SC three times a week).

Completed
3
1050
Europe
Natalizumab, Rebif 44 micrograms, Not Applicable, Concentrate for solution for infusion, Solution for injection, Rebif 44 micrograms
Biogen Idec GmbH
Male and female subjects with relapsing multiple sclerosis previously treated with interferon beta-1a (22 mcg or 44 mcg, SC three times a week).
 
 
NCT00249860: A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects

Completed
3
257
RoW
Interferon-beta-1a, Placebo, Ribavirin plus Interferon-beta-1a
EMD Serono, Merck Pte. Ltd., Singapore
Hepatitis C
08/05
08/05
RNF, NCT00110396 / 2004-003799-13: Rebif New Formulation () in Relapsing Forms of Multiple Sclerosis

Completed
3
260
US
Interferon-beta-1a FBS-free/HSA-free
EMD Serono, Pfizer
Multiple Sclerosis
04/07
04/07
REFORMS, NCT00428584: RNF and Betaseron® Tolerability Study

Checkmark P3 data: REFORMS
Dec 2012 - Dec 2012: P3 data: REFORMS
Completed
3
129
US
New Formulation of rebif - human interferon beta-1a, Interferon beta -1b
EMD Serono, Pfizer
Relapsing Remitting Multiple Sclerosis (RRMS)
11/07
09/09
TRANSFER, NCT00619307 / 2006-005972-42: Transition to Rebif New Formulation

Completed
3
117
Europe
Rebif New Formulation + prophylactic Ibuprofen, Rebif New Formulation + ibuprofen PRN
Merck KGaA, Darmstadt, Germany
Relapsing Multiple Sclerosis
04/08
04/08
CIS-ON, NCT00287079: A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome

Completed
3
35
Canada
Rebif®, No Treatment
Merck KGaA, Darmstadt, Germany, EMD Serono Canada Inc.
Clinically Isolated Syndrome
11/08
11/08
IMPROVE, NCT00441103 / 2006-003037-32: A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

Completed
3
180
Canada, Europe, RoW
Rebif® New Formulation (IFN-beta-1a, RNF), IFN-beta-1a, Placebo
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
11/08
02/09
NCT00735007 / 2008-000499-25: 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Completed
3
106
US, Canada, Europe
Rebif® New Formulation (RNF) using RebiSmartTM
EMD Serono
Multiple Sclerosis
01/09
 
RebiQoL, NCT00472797: Rebif New Formulation (RNF) Quality of Life (QOL) Study

Completed
3
232
US
Rebif New Formulation Non Titrated, Rebif New Formulation Titrated
EMD Serono
Relapsing Multiple Sclerosis
02/09
11/09
NCT00958009: The Multicenter, Open-label, Single-use Autoinjector Convenience Study

Checkmark CMSC 2015
Jun 2015 - Jun 2015: CMSC 2015
Completed
3
109
US
Rebidose®
EMD Serono
Multiple Sclerosis
04/10
06/10
REFLEX, NCT00404352 / 2006-002982-38: REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

Checkmark REFLEX
Jan 2014 - Jan 2014: REFLEX
Checkmark REFLEX
Dec 2013 - Dec 2013: REFLEX
Checkmark Data, MS
More
Completed
3
517
Canada, Europe, RoW
RNF, Rebif, Placebo
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
08/10
07/11
Performs, NCT01036165: A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

Checkmark AAN 2015: Multiple sclerosis (PERFORMS)
Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (PERFORMS)
Completed
3
103
US
RebiSmart™
EMD Serono
Multiple Sclerosis
08/10
08/10
CARE-MS I, NCT00530348 / 2007-001161-14 / ACTRN12608000435381: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

Checkmark CARE-MS I trial
Nov 2015 - Nov 2015: CARE-MS I trial
Checkmark ECTRIMS 2015: Multiple sclerosis (CARE-MS I extension)
Sep 2015 - Sep 2015: ECTRIMS 2015: Multiple sclerosis (CARE-MS I extension)
Checkmark CARE-MS I & CARE-MS II
More
Completed
3
581
US, Canada, Europe, RoW
Alemtuzumab, Lemtrada, Interferon beta-1a, Rebif®
Genzyme, a Sanofi Company, Bayer
Multiple Sclerosis, Relapsing-Remitting
04/11
04/11
ORACLE MS, NCT00725985 / 2008-003706-33: Oral Cladribine in Early Multiple Sclerosis (MS)

Checkmark AAN 2016: ORACLE-MS
Mar 2016 - Mar 2016: AAN 2016: ORACLE-MS
Checkmark ORACLE MS
Feb 2014 - Feb 2014: ORACLE MS
Checkmark AAN 2013
More
Completed
3
617
Europe, Canada, US, RoW
Cladribine, Placebo, Rebif® new formulation (RNF)
EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
07/11
04/12
REFLEXION, NCT00813709 / 2008-004954-34: Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)

Checkmark AAN 2015: Multiple sclerosis (REFLEX/REFLEXION)
Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (REFLEX/REFLEXION)
Checkmark Data
Apr 2012 - Apr 2012: Data
Completed
3
402
Canada, Europe, RoW
RNF, Rebif®, Placebo
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Clinically Isolated Syndrome
08/11
09/13
CARE-MS II, NCT00548405 / 2007-001162-32 / ACTRN12608000426381: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

Checkmark AAN 2016: CARE-MS II
Mar 2016 - Mar 2016: AAN 2016: CARE-MS II
Checkmark ECTRIMS 2015: Multiple sclerosis (CARE-MS II)
Sep 2015 - Sep 2015: ECTRIMS 2015: Multiple sclerosis (CARE-MS II)
Checkmark CMSC 2015
More
Completed
3
840
US, Canada, Europe, RoW
Alemtuzumab 12 mg, Lemtrada, Alemtuzumab 24 mg, Interferon beta-1a, Rebif®
Genzyme, a Sanofi Company, Bayer
Multiple Sclerosis, Relapsing-Remitting
09/11
09/11
TENERE, NCT00883337 / 2008-006226-34: A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis

Checkmark ISPOR: TENERE
Nov 2014 - Nov 2014: ISPOR: TENERE
Checkmark TENERE
Oct 2013 - Oct 2013: TENERE
Checkmark Data - ENS 2012
More
Completed
3
324
Canada, Europe, RoW
Interferon β-1a, Rebif®, Teriflunomide, HMR1726
Sanofi
Multiple Sclerosis
09/11
05/15
SURPASS, NCT01058005 / 2009-015556-15: Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Checkmark Interim data
Oct 2010 - Oct 2010: Interim data
Terminated
3
84
US, Canada, Europe, RoW
BG00002 (natalizumab), Tysabri, interferon beta-1a, Rebif, glatiramer acetate, Copaxone
Biogen, Elan Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
04/12
04/12
2013-003126-83: Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.

Completed
3
1176
Europe, RoW
Avonex, MSC2430913A or ONO-4641 (to be used as synonyms), Film-coated tablet, Solution for infusion in pre-filled syringe, Avonex
Merck KGaA, Merck KGaA
Relapsing multiple sclerosis, Multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
OPERA I, NCT01247324 / 2010-020337-99: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Checkmark CMSC 2016: OPERA I and OPERA II
Jun 2016 - Jun 2016: CMSC 2016: OPERA I and OPERA II
Checkmark AAN 2016: OPERA I & OPERA II
Mar 2016 - Mar 2016: AAN 2016: OPERA I & OPERA II
Checkmark ACTRIMS Forum 2016: Multiple sclerosis (OPERA I & OPERA II)
More
Completed
3
821
Europe, US, RoW
Interferon beta-1a, Rebif, Ocrelizumab-matching placebo, Ocrelizumab, RO4964913, Interferon beta-1a-matching placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
04/15
12/22
OPERA II, NCT01412333 / 2010-020315-36: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Checkmark CMSC 2016: OPERA I and OPERA II
Jun 2016 - Jun 2016: CMSC 2016: OPERA I and OPERA II
Checkmark AAN 2016: OPERA I & OPERA II
Mar 2016 - Mar 2016: AAN 2016: OPERA I & OPERA II
Checkmark ACTRIMS Forum 2016: Multiple sclerosis (OPERA I & OPERA II)
More
Completed
3
835
Europe, Canada, US, RoW
Interferon beta-1a, Rebif, Ocrelizumab-matching placebo, Ocrelizumab, RO4964913, Interferon beta-1a-matching placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
05/15
12/22
2006-004937-13: multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis

Ongoing
3
360
Europe
AZATIOPRINA HEX. 50CPR 50MG BL, REBIF SC 12SIR 6000000UI 22MCG, BETAFERON SC 15F 0,25MG 15SIR, REBIF SC 12SIR 12000000UI44MCG, AVONEX IM 4SIR 30MCG/0,5ML 4AG, AZATIOPRINA HEX. 50CPR 50MG BL, REBIF SC 12SIR 6000000UI 22MCG, BETAFERON SC 15F 0,25MG 15SIR, REBIF SC 12SIR 12000000UI44MCG, AVONEX IM 4SIR 30MCG/0,5ML 4AG
Universita di Firenze
patients with relapsing remitting multiple sclerosis
 
 
2012-005086-12: Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulin

Ongoing
3
81
Europe
Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml, Octagam 50 mg/ml, Copaxone 20 mg/ml, Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml, Octagam 50 mg/ml, Copaxone 20 mg/ml, Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml
Octapharma AG, Octapharma AG
relapsing multiple sclerosis
 
 
2013-002351-15: Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.

 
3
88
Europe
Avonex, MSC2430913A or ONO-4641 (to be used as synonyms), Avonex, Avonex
Merck KGaA, Merck KGaA
Relapsing remitting multiple sclerosis
 
08/14
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
EVOLUTION MS1, NCT04032158 / 2018-004701-11: Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Terminated
3
3
Europe, US
Evobrutinib, M2951, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis
04/20
04/20
EVOLUTION MS2, NCT04032171 / 2018-004700-19: Study of Evobrutinib in Participants With RMS

Terminated
3
1
Europe, US
Evobrutinib, M2951, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis
05/20
05/20
MITOX-REBIF, NCT02937285 / 2004-001601-10: National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis

Completed
3
35
Europe
Interferon beta 1a, REBIF, Mitoxantrone, ELSEP
Rennes University Hospital
Multiple Sclerosis
05/20
05/20
2020-002060-31: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care Mezinárodní randomizovaná studie další léčby COVID-19 u hospitalizovaných pacientů, kteří jsou léčeni standardní péčí.

Ongoing
3
100000
Europe
remdesivir, Lyophilisate for solution for infusion, Coated tablet, Powder and solution for solution for injection, Kaletra, Rebif, Plaquenil
Masaryk University, World Health Organisation, Masaryk University
COVID-19 COVID-19, COVID-19 COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
NCT04492475: Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

Completed
3
969
Japan, US, RoW
Interferon beta-1a, Placebo, Remdesivir
National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
12/20
12/20
DisCoVeRy, NCT04315948 / 2020-000936-23: Trial of Treatments for COVID-19 in Hospitalized Adults

Hourglass Dec 2021 - Dec 2021 : Data from DisCoVeRy trial for treatment of COVID-19 in hospitalized adults
Completed
3
1552
Europe
Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A, Hydroxychloroquine, Standard of care, AZD7442, Placebo
Institut National de la Santé Et de la Recherche Médicale, France
Corona Virus Infection
07/22
09/23
NCT03283397: A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS

Recruiting
3
400
RoW
EK-12, INF beta-1a
Bosnalijek D.D, MonitorCRO
Multiple Sclerosis, Relapsing-Remitting
12/23
07/24
NCT02727907: Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Completed
2/3
163
RoW
BCD-033 (interferon beta 1a), Rebif (interferon beta 1a), Placebo
Biocad
Multiple Sclerosis
11/16
08/17
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21

Download Options